Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05724901 · ClinicalTrials.gov registry record

At-Home Gait Assessment

A clinical trial, sponsored by NYU Langone Health.

Completed
Registry status
30
Enrollment target

NCT05724901: Completed study, sponsored by NYU Langone Health.

NCT05724901 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05724901 has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
30 participants
Enrollment target

Study Summary

The goal of this study is to validate an MS Gait Remote Capture and Analysis (MS-GRCA) system based on wearable shoe-based motion sensors for home-based and repeatable gait assessments.

Primary Outcome

Measured using sensor-based gait assessment

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-01-11
Est. Completion 2024-01-04
NYU Langone Health

1,164 total trials

What the finished NCT05724901 record still lists

NCT05724901 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT05724901 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05724901 about?

NCT05724901 is a clinical study titled "At-Home Gait Assessment". The goal of this study is to validate an MS Gait Remote Capture and Analysis (MS-GRCA) system based on wearable shoe-based motion sensors for home-based and repeatable gait assessments.

What is the current status of trial NCT05724901?

This trial is currently completed. The enrollment target is 30 participants. The study started on 2023-01-11. Estimated completion is 2024-01-04.

Who is sponsoring clinical trial NCT05724901?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05724901, the US trial registry maintained by the National Library of Medicine. NCT05724901 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.